EGFR-TKIs Versus Taxanes Agents in Therapy for Nonsmall-cell Lung Cancer Patients: A PRISMA-compliant Systematic Review with Meta-analysis and Meta-regression

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2016 Dec 16

PMID 27977598

Citations 6

Authors

Na An

Yingshi Zhang

Huibin Niu

Zuojing Li

Jiayi Cai

Qingchun Zhao

Qing Li

Affiliations

Soon will be listed here.

Abstract

Background: Currently, the nonsmall-cell lung cancer (NSCLC) is a worldwide disease, which has very poor influence on life quality, whereas the therapeutic effects of drugs for it are not satisfactory. The aim of our PRISMA-compliant systematic review and meta-analysis was to compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with Taxanes in patients with lung tumors.

Methods: We collected randomized controlled trials (RCTs) of EGFR-TKIs (gefitinib, erlotinib) versus Taxanes (docetaxel, paclitaxel) for the treatment of NSCLC by searching PubMed, EMbase, and the Cochrane library databases until April, 2016. The extracted data on progression-free survival (PFS), progression-free survival rate (PFSR), overall survival (OS), overall survival rate (OSR), objective response rate (ORR), disease control rate (DCR), quality of life (QoL), and adverse event rates (AEs) were pooled. Disease-relevant outcomes were evaluated using RevMan 5.3.5 software and STATA 13.0 software.

Results: We systematically searched 26 RCTs involving 11,676 patients. The results showed that EGFR-TKIs could significantly prolong PFS (hazard ratio [HR] = 0.78, 95% confidence interval [CI]: 0.66-0.92) and PFSR (risk ratio [RR] = 2.10, 95% CI: 1.17-3.77), and improve ORR (RR = 1.62, 95% CI: 1.38-1.91) and QoL. EGFR-TKIs had similar therapeutic effects to taxanes with respect to OS (HR = 1.00, 95% CI: 0.95-1.05) and OSR (RR = 1.03, 95% CI: 0.94-1.14). Furthermore, there were no significant differences between them in DCR (RR = 0.95, 95% CI: 0.88-1.03). Finally, EGFR-TKIs were superior to taxanes in most of all grades or grade ≥3 AEs.

Conclusion: In the efficacy and safety evaluation, EGFR-TKIs had an advantage in the treatment of NSCLC, especially for patients with EGFR mutation-positive. The project was prospectively registered with PROSPERO database of systematic reviews, with number CRD42016038700.

Citing Articles

Machine Learning in Diagnosis and Prognosis of Lung Cancer by PET-CT.

Yuan L, An L, Zhu Y, Duan C, Kong W, Jiang P Cancer Manag Res. 2024; 16:361-375.

PMID: 38699652 PMC: 11063459. DOI: 10.2147/CMAR.S451871.

Combination of F-Fluorodeoxyglucose PET/CT Radiomics and Clinical Features for Predicting Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.

Li S, Li Y, Zhao M, Wang P, Xin J Korean J Radiol. 2022; 23(9):921-930.

PMID: 36047542 PMC: 9434738. DOI: 10.3348/kjr.2022.0295.

Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?.

Justo N, Nilsson J, Korytowsky B, Dalen J, Madison T, McGuire A PLoS One. 2020; 15(5):e0232669.

PMID: 32396541 PMC: 7217468. DOI: 10.1371/journal.pone.0232669.

Value of pre-therapy F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer.

Zhang J, Zhao X, Zhao Y, Zhang J, Zhang Z, Wang J Eur J Nucl Med Mol Imaging. 2019; 47(5):1137-1146.

PMID: 31728587 DOI: 10.1007/s00259-019-04592-1.

The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.

Zhang Y, Feng Y, Zhu H, Xiong T, Hou Y, Song J Medicine (Baltimore). 2018; 97(30):e11648.

PMID: 30045314 PMC: 6078676. DOI: 10.1097/MD.0000000000011648.

References

Wu Y, Fukuoka M, Mok T, Saijo N, Thongprasert S, Yang J . Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer. 2013; 81(2):280-7. DOI: 10.1016/j.lungcan.2013.03.004. View

Xu J, Liu X, Yang S, Zhang X, Shi Y . [Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases]. Zhongguo Fei Ai Za Zhi. 2015; 18(9):554-8. PMC: 6000113. DOI: 10.3779/j.issn.1009-3419.2015.09.05. View

Park K, Tan E, OByrne K, Zhang L, Boyer M, Mok T . Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X. View

Douillard J, Shepherd F, Hirsh V, Mok T, Socinski M, Gervais R . Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2009; 28(5):744-52. DOI: 10.1200/JCO.2009.24.3030. View

Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K . Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs. 2006; 17(4):401-9. DOI: 10.1097/01.cad.0000203381.99490.ab. View

Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Taira T . Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. Springerplus. 2015; 4:152. PMC: 4395619. DOI: 10.1186/s40064-015-0929-3. View

Jiang J, Huang L, Liang X, Zhou X, Huang R, Chu Z . Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Acta Oncol. 2010; 50(4):582-8. DOI: 10.3109/0284186X.2010.546368. View

Yang Y, Zhang B, Li R, Liu B, Wang L . EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature. Oncol Lett. 2016; 11(5):3546-3550. PMC: 4841118. DOI: 10.3892/ol.2016.4409. View

Thongprasert S, Duffield E, Saijo N, Wu Y, Yang J, Chu D . Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011; 6(11):1872-80. DOI: 10.1097/JTO.0b013e31822adaf7. View

10.

Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K . Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008; 26(26):4244-52. DOI: 10.1200/JCO.2007.15.0185. View

11.

Wu Y, Chu D, Han B, Liu X, Zhang L, Zhou C . Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol. 2012; 8(3):232-43. DOI: 10.1111/j.1743-7563.2012.01518.x. View

12.

Morere J, Brechot J, Westeel V, Gounant V, Lebeau B, Vaylet F . Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer. 2010; 70(3):301-7. DOI: 10.1016/j.lungcan.2010.03.003. View

13.

Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H . Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012; 17(6):863-70. PMC: 3380886. DOI: 10.1634/theoncologist.2011-0426. View

14.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

15.

Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H . Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014; 32(18):1902-8. DOI: 10.1200/JCO.2013.52.4694. View

16.

Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K . Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol. 2011; 7(1):115-21. DOI: 10.1097/JTO.0b013e3182307f98. View

17.

Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S . Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014; 9(2):189-94. PMC: 4132025. DOI: 10.1097/JTO.0000000000000048. View

18.

Kendra K, Plummer R, Salgia R, OBrien M, Paul E, Suttle A . A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol Cancer Ther. 2014; 14(2):461-9. DOI: 10.1158/1535-7163.MCT-14-0431. View

19.

Yamamoto N, Nishiwaki Y, Negoro S, Jiang H, Itoh Y, Saijo N . Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients. J Thorac Oncol. 2010; 5(7):1042-7. DOI: 10.1097/JTO.0b013e3181da36db. View

20.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View